| Literature DB >> 32993548 |
Anthony Batte1, Michelle C Starr2, Andrew L Schwaderer2, Robert O Opoka3, Ruth Namazzi3, Erika S Phelps Nishiguchi4, John M Ssenkusu5, Chandy C John6, Andrea L Conroy7.
Abstract
BACKGROUND: Acute kidney injury (AKI) is increasingly recognized as a consequential clinical complication in children with severe malaria. However, approaches to estimate baseline creatinine (bSCr) are not standardized in this unique patient population. Prior to wide-spread utilization, bSCr estimation methods need to be evaluated in many populations, particularly in children from low-income countries.Entities:
Keywords: Acute kidney injury; Baseline creatinine; Methods; Mortality; Pediatric; Pottel; Schwartz; Severe malaria; Sub-Saharan Africa; Undernutrition
Year: 2020 PMID: 32993548 PMCID: PMC7526147 DOI: 10.1186/s12882-020-02076-1
Source DB: PubMed Journal: BMC Nephrol ISSN: 1471-2369 Impact factor: 2.388
Fig. 1Flow chart of the two study populations. Between 2008 and 2017, 289 community children and 1078 children with severe malaria were enrolled in two severe malaria studies that recruited children from Kampala and Jinja in Uganda. One community child from each cohort with evidence of underlying kidney disease (estimated GFR < 90 mL/min per 1.73m2) was excluded from the study
Fig. 2Overview of approaches used to evaluate estimates of baseline serum creatinine. a Overview of GFR-based and direct SCr-based methods to estimate baseline serum creatinine (bSCr) in community children. Linear regression models using the height and age of community children were used for direct estimation of ebSCrheightCC and ebSCrageCC. b The estimated bSCr and measured SCr were compared in community children to evaluate the bias, precision and accuracy of methods. c AKI was defined in children with severe malaria using the different approaches to estimate bSCr, and the relationship between AKI and mortality was evaluated
Demographic characteristics of study population
| Community children (CC) | Severe Malaria ( | ||||
|---|---|---|---|---|---|
| Cohort #1 ( | Cohort #2 ( | Combined ( | |||
| Enrollment years | 2008–2013 | 2014–2017 | 2008–2017 | 2008–2017 | – |
| Age, years | |||||
| Mean (SD) | 4.01 (2.03) | 2.22 (1.02) | 3.28 (1.91) | 2.83 (1.62) | 0.0001 |
| Median (IQR) | 3.59 (2.61, 4.62) | 2.21 (1.39, 3.09) | 3.00 (2.06, 3.92) | 2.50 (1.75, 3.47) | |
| Min, Max | 1.55, 11.44 | 0.53, 3.96 | 0.53, 11.44 | 0.46, 11.69 | |
| Age category, n(%) | |||||
| < 1 | 0 (0.0) | 18 (15.4) | 18 (6.2) | 74 (6.9) | 0.001 |
| 1- < 2 | 11 (6.4) | 35 (29.9) | 46 (15.9) | 296 (27.5) | |
| 2–5 | 128 (74.4) | 64 (54.7) | 192 (66.4) | 609 (56.5) | |
| > 5 | 33 (19.2) | 0 (0.0) | 33 (11.4) | 99 (9.2) | |
| Sex, % F | 94 (54.7) | 55 (47.0) | 149 (51.2) | 455 (42.2) | 0.004 |
| Height, cm | 96.6 (13.6) | 83.7 (10.4) | 91.4 (13.9) | 88.8 (12.8) | 0.0032 |
| Weight, kg | 14.7 (4.4) | 11.6 (2.6) | 13.5 (4.1) | 12.0 (3.6) | < 0.0001 |
| BMI, kg/m2 | 15.6 (1.7) | 16.5 (1.7) | 15.9 (1.7) | 15.1 (1.8) | < 0.0001 |
| Weight-for-agea | −0.82 (0.98) | − 0.47 (1.08) | − 0.68 (1.04) | −1.10 (1.10) | < 0.0001 |
| Underweighta n (%) | 21 (12.5) | 9 (7.7) | 30 (10.5) | 209 (19.6) | < 0.0001 |
| Height-for-ageb | −1.25 (1.13) | −1.26 (1.34) | − 1.25 (1.22) | −1.17 (1.35) | 0.3602 |
| Stunted, n (%) | 43 (25.0) | 36 (30.8) | 79 (27.3) | 259 (24.1) | 0.250 |
| Weight-for-height < 5c | −0.15 (1.25) | 0.30 (1.02) | 0.05 (1.17) | −0.65 (1.32) | < 0.0001 |
| BMI-for-age > 5d | −0.30 (0.84) | – | −0.30 (0.84) | − 0.80 (1.43) | 0.0635 |
| Wasted, n (%)e | 8 (4.7) | 3 (2.6) | 11 (3.8) | 156 (14.6) | < 0.0001 |
| Systolic BP | 94.1 (10.2) | 98.5 (11.7) | 95.9 (11.1) | 95.9 (13.0) | 0.9164 |
| Diastolic BP | 60.9 (10.6) | 59.1 (9.8) | 60.2 (10.4) | 56.9 (12.1) | < 0.0001 |
| Enrollment SCr | |||||
| Mean ± SD | 0.31 (0.08) | 0.26 (0.07) | 0.29 (0.08) | 0.48 (0.48) | < 0.0001 |
| Median (IQR) | 0.30 (0.24, 0.35) | 0.25 (0.20, 0.30) | 0.28 (0.23, 0.33) | 0.38 (0.29, 0.49) | |
| Min, Maxa | 0.19, 0.56 | 0.19, 0.46 | 0.19, 1.0 | 0.19, 7.3 | |
| Enrollment eGFR, ml/min per 1.73m2 | 136.4 (29.3) | 137.7 (30.5) | 136.9 (29.8) | 99.5 (38.2) | < 0.0001 |
Data are presented as mean (SD) unless otherwise indicated. Undernutrition (weight-for-age z score < −2), stunted (height-for-age z score < −2), wasted (weight-for-height or bmi-for-age z score < −2) according to WHO 2006 (age 0–5 years) and 2007 (5–12 years) reference standards
aWeight-for-age z scores available for children < 10 years (Cohort #1, CC n = 168, SM n = 476; Cohort #2, CC n = 117, SM n = 591; Combined, CC n = 285; SM, n = 1067)
bHeight-for-age z scores (Cohort #1, CC n = 168, SM n = 479; Cohort #2, CC n = 117, SM n = 598; Combined, CC n = 289; SM, n = 1077)
cWeight-for-height z scores available for children < 5 years (Cohort #1, CC n = 139, SM n = 388; Cohort #2, CC n = 117, SM n = 591; Combined, CC n = 256; SM, n = 979)
dBMI-for-age z scores available for children ≥5 years of age (Cohort #1, CC n = 33, SM = 91; Cohort #2, CC n = 0, SM n = 0; Combined, CC n = 33; SM, n = 91)
eWasted (Cohort #1, CC n = 172, SM = 479; Cohort #2, CC n = 117, SM n = 591; Combined, CC n = 289; SM, n = 1070)
Fig. 3Estimated GFR and bSCr in healthy community children based on method to estimate bSCr. Graphs showing the GFR calculated off the estimated bSCr using the Bedside Schwartz equation on the left y-axis in black and the estimated bSCr in grey on the right y-axis. The top row represents approaches starting with an assumed GFR and back-calculating bSCr using either the Bedside Schwartz equation (a, c) or the Pottel height-independent equation (b). The bottom row represents approaches to estimate bSCr directly using the upper limit of normal (d) or height (e) and age (f) based estimates from community children. The eGFR for each graph was calculated using the Bedside Schwartz equation using the bSCr and height at enrollment, where eGFR = (0.413*height)/bSCr
Agreement between measured and estimated serum creatinine in community children
| Measured | Estimated | ||||||
|---|---|---|---|---|---|---|---|
| bSCr back-calculated from GFR | bSCr estimated directly | ||||||
| SCr | bSCrGFRSchwartz120 | bSCrGFRPottel120 | bSCrGFRSchwartz137 | bSCrupperlimit | bSCrheightCC | bSCrageCC | |
| Mean (SD) (mg/dL) | 0.29 (0.08) | 0.31 (0.05) | 0.29 (0.05) | 0.28 (0.04) | 0.40 (0.06) | 0.29 (0.04) | 0.29 (0.04) |
| Median (IQR) (mg/dL) | 0.28 (0.23, 0.33) | 0.31 (0.28, 0.34) | 0.28 (0.26, 0.30) | 0.27 (0.25, 0.30) | 0.39 (0.35, 0.42) | 0.28 (0.26, 0.31) | 0.28 (0.26, 0.30) |
| Wilcoxona | – | *** | NS | NS | *** | NS | NS |
| Min, max (mg/dL) | 0.19, 0.56 | 0.23, 0.34 | 0.22, 0.48 | 0.20, 0.44 | 0.35, 0.71 | 0.22, 0.44 | 0.23, 0.46 |
| Correlation, SCr (r) | – | 0.495 | 0.485 | 0.495 | 0.407 | 0.495 | 0.485 |
| Bias (mg/dL) | – | 0.025*** | −0.002 (NS) | −0.014*** | 0.11*** | −0.002 (NS) | −0.002 (NS) |
| Precision (mg/dL) | – | 0.07 | 0.07 | 0.07 | 0.08 | 0.07 | 0.07 |
| Accuracy | |||||||
| P10, % | – | 24% | 35% | 33% | 8% | 29% | 35% |
| P30, % | – | 71% | 79% | 82% | 33% | 80% | 78% |
| Proportional Bias | – | −0.66 ± 0.06 *** | − 0.70 ± 0.06*** | −0.81 ± 0.06*** | −0.35 ± 0.07*** | −0.91 ± 0.06*** | −0.88 ± 0.06*** |
Standard deviation (SD), IQR: Inter-quartile range, r: Spearman’s rho, NS: Not significant, *p < 0.05, **p < 0.001, *** p < 0.0001
aWilcoxon signed rank test (paired) for comparison of entire distribution with measured creatinine
Bias: mean difference between estimated and measured creatinine. To estimate fixed bias, we compared value of the difference to a value of 0 using a one sample t-test
Precision: one standard deviation of the Bias
Proportional bias: the slope of the regression line of the differences between estimated and measured creatinine against the average of estimated and measured creatinine. A slope of 0 means no proportional bias
Accuracy reflects the percentage of estimated SCr within 10 or 30% of the measured SCr, where accuracy = [(measured SCr- estimated SCr)/measured SCr] *100
P value is the significance of the deviation of the slope from 0. ***p < 0.0001
Fig. 4Bland Altman analysis comparing measured SCr in community children versus different methods to estimate bSCr. Graphs show the difference in estimated baseline SCr (bSCr) and measured (mSCr) compared to the average. The top row represents approaches starting with an assumed GFR and back-calculating bSCr using either the Bedside Schwartz equation (a, c) or the Pottel height-independent equation (b). The bottom row represents approaches to estimate bSCr directly using the upper limit of normal (d) or height (e) and age (f) based estimates from the community children. The bias represents the difference between the mSCr and estimated bSCr where the significance of bias was assessed using a one sample t-test comparing the mean bias to 0. The precision is represented as one standard deviation of the mean difference. Proportional bias was evaluated by testing if the slope of the linear regression model of the differences between estimated and measured creatinine against the average of estimated and measured creatinine differed from zero. Proportional bias represents the slope (B1) + SE (standard error) and the asterisks indicate whether the slope is statistically different from zero. Not significant (NS, where p > 0.05), *p < 0.05, **p < 0.001, ***p < 0.0001
Estimates of bSCr and eGFR in healthy community children based on age at enrollment
| Age < 1 years | Age 1 to < 2 years | Age 2 to < 5 years | Age ≥ 5 years | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| bSCr | eGFR | bSCr | eGFR | bSCr | eGFR | bSCr | eGFR | SCr | eGFR | |
| Measured SCr | 0.23 (0.04) | 127.3 (20.8) | 0.25 (0.06) | 135.9 (29.0) | 0.29 (0.07) | 138.2 (30.8) | 0.37 (0.08) | 136.0 (28.7) | < 0.001 | 0.484 |
| bSCrGFRSchwartz120a | 0.24 (0.01) | 120 (0.0) | 0.27 (0.01) | 120 (0.0) | 0.32 (0.03) | 120 (0.0) | 0.41 (0.04) | 120 (0.0) | < 0.001 | – |
| bSCrGFRPottel120b | 0.23 (0.003) | 126.8 (4.6) | 0.25 (0.01) | 131.9 (5.0) | 0.29 (0.02) | 132.7 (7.0) | 0.39 (0.05) | 126.8 (8.0) | < 0.001 | < 0.001 |
| bSCrGFRSchwartz137a | 0.21 (0.009) | 137 (0.0) | 0.24 (0.01) | 137 (0.0) | 0.28 (0.02) | 137 (0.0) | 0.36 (0.03) | 137 (0.0) | < 0.001 | < 0.001 |
| bSCrupperlimitc | 0.39 (0.0) | 73.3 (3.1) | 0.35 (0.0) | 92.9 (4.5) | 0.39 (0.03) | 97.5 (6.8) | 0.54 (0.07) | 90.8 (7.1) | < 0.001 | < 0.001 |
| bSCrCCheightd | 0.23 (0.01) | 125.9 (0.8) | 0.25 (0.01) | 128.4 (0.9) | 0.29 (0.02) | 131.0 (1.4) | 0.36 (0.03) | 134.7 (1.2) | < 0.001 | < 0.001 |
| bSCrCCagee | 0.23 (0.003) | 121.8 (4.5) | 0.25 (0.01) | 128.8 (5.0) | 0.29 (0.02) | 132.5 (7.2) | 0.37 (0.04) | 131.6 (7.2) | < 0.001 | < 0.001 |
1P value calculated using ANOVA to evaluate mean differences across age categories
aBedside Schwartz equation (eGFR = 0.413*height/SCr) used to back calculate creatinine assuming a normal of 120 mL/min/1.73m2 or 137 mL/min/1.73m2 (mean of the community children)
bPottel equation (eGFR = 107.3/(SCr/Q), where Q = 0.0270*age + 0.2329) used to back calculate creatinine assuming a normal of 120 mL/min per 1.73m2
cUpper limit using Ceriotti et al., Clin Chem 2008 54:3
dLinear regression model of height vs. creatinine using healthy community children to estimate baseline creatinine from model
eLinear regression model of age vs. creatinine using healthy community children to estimate baseline creatinine from model
Fig. 5AKI prevalence and mortality across AKI stages and age categories in children with severe malaria. Bar graphs showing the frequency of AKI (a, c) or AKI mortality (b, d) using different approaches to estimate baseline serum creatinine (bSCr). b AKI severity was associated with increased mortality irrespective of method used to estimate bSCr (p < 0.0001 for all, Pearson’s Chi square test). c AKI prevalence differed across age categories when GFR based methods were used to estimate bSCr *p < 0.05. There was no difference in AKI prevalence when using approaches to directly estimate SCr (ns, p > 0.05). d AKI was associated with increased mortality across age categories
Relationship between AKI and mortality
| AKI Classification | Mortality no AKI | Mortality AKI | Risk Ratio | Model Fit | AKI Area under ROC | |||
|---|---|---|---|---|---|---|---|---|
| AIC | BIC | Sensitivity | Specificity | |||||
| AKISchwartz120 | 25 (3.4) | 51 (15.1) | 4.41 (2.78, 7.00) | 0.473 | − 6990.3 | 0.69 (0.64, 0.75) | 67.1% | 71.3% |
| AKIPottel120 | 17 (2.7) | 59 (13.6) | 5.13 (3.03, 8.68) | 0.469 | − 6994.0 | 0.70 (0.65, 0.75) | 77.6% | 62.4% |
| AKISchwartz137 | 17 (2.8) | 59 (12.6) | 4.50 (2.66, 7.62) | 0.477 | − 6986.2 | 0.68 (0.63, 0.73) | 77.6% | 59.2% |
| AKIupperlimit | 43 (4.7) | 33 (19.6) | 4.17 (2.74, 6.36) | 0.479 | − 6984.1 | 0.65 (0.59, 0.71) | 43.4% | 86.5% |
| AKIheightCC | 20 (3.1) | 56 (13.3) | 4.28 (2.61, 7.03) | 0.477 | −6986.3 | 0.69 (0.63, 0.74) | 73.7% | 63.4% |
| AKIageCC | 18 (2.8) | 58 (13.7) | 4.99 (2.98, 8.34) | 0.470 | − 6993.6 | 0.70 (0.65, 0.75) | 76.3% | 63.5% |
Risk ratio estimated using a generalized linear model with binomial family and log link adjusting for age and sex